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Abstract
Background: Dynamin 1 is a protein involved in the synaptic vesicle cycle,
which facilitates the exocytosis of neurotransmitters necessary for normal signal-
ing and development in the central nervous system. Pathogenic variants in DNM1
have been implicated in global developmental delay (DD), severe intellectual dis-
ability (ID), and notably, epileptic encephalopathy. All previously reported DNM1
pathogenic variants causing this severe phenotype occur in the GTPase and Mid-
dle domains of the dynamin 1 protein.
Methods: We used whole-exome sequencing to characterize the molecular basis
of DD and autistic symptoms in two identical siblings.
Results: The twin siblings exhibit mild to moderate ID and autistic symptoms
but no epileptic encephalopathy. Exome sequencing revealed a genetic variant,
c.1603A>G (p.Lys535Glu), in the PH domain of dynamin 1. Previous in vitro
studies showed that mutations at Lys535 inhibit endocytosis and impair PH loop
binding to PIP2.
Conclusions: Our data suggest a previously undescribed milder phenotype associ-
ated with a missense genetic variant in the PH domain of dynamin 1.
KEYWORD S
developmental delay, domain, dynamin 1, epileptic encephalopathy, intellectual disability, synaptic
vesicle
1 | BACKGROUND
Neurotransmission in the central nervous system depends
on synaptic vesicle transport. Neurotransmitters are taken
up by exocytotic vesicles which fuse with the plasma mem-
brane, releasing neurotransmitters into the synapse (Sudhof,
2004). Neurotransmitters in the synapse are degraded or
taken up into the presynaptic axon. Vesicle endocytosis,
when vesicles bud off from the plasma membrane into the
presynaptic axon, is mediated by proteins including amphy-
sin, endophilin, clathrin, and dynamin (Rizzoli, 2014).
Newly synthesized or retrieved neurotransmitters enter
these new vesicles and restart the cycle (Takei, 1996).
The Dynamin family of proteins interact with clathrin in
the vesicle budding cycle and participate in the scission
between the cell membrane and vesicle wall. After the
invagination of the lipid membrane, dynamin binds GTP
and its alpha helixes wrap around and pinch the budding
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vesicle. Next, dynamin uses the energy from GTP hydroly-
sis to sever the membrane tubules and complete vesicle fis-
sion (Antonny et al., 2016). This process is critical for the
synaptic vesicle cycle (McNiven, 2000). Dynamin proteins
have five domains; the GTPase domain is the largest and
best understood, followed by a middle domain, pleckstrin
homology (PH) domain, coiled coil (CC) domain, and a
proline-rich domain (PRD) (McNiven, 2000). The PH
domain is thought to interact directly with the lipid bilayer
(Vallis, Wigge, Marks, Evans, & McMahon, 1999).
The DNM1 gene (MIM 602377) codes for dynamin 1
and is mainly expressed in the central nervous system
(Romeu & Arola, 2014). Pathogenic DNM1 variants affect
brain development and function and cause epileptic
encephalopathy associated with global developmental delay
(DD) (Allen et al., 2016; Deng et al., 2016; Epi4K Consor-
tium; Epilepsy Phenome/Genome Project, 2013; Euro E-
RESC, EpilepsyPhenome/Genome P, Epi4K Constorium,
2014; Nakashima et al., 2016). Previously reported patients
with DNM1-related disorder carry pathogenic variants in
the GTPase or middle domains, but never in the PH
domain (Allen et al., 2016; Deng et al., 2016; Epi4K Con-
sortium; Epilepsy Phenome/Genome Project, 2013; Euro E-
RESC, EpilepsyPhenome/Genome P, Epi4K Constorium,
2014; Nakashima et al., 2016).
Here, we report 8-year-old identical twin sisters with a
de novo p.Lys535Glu likely pathogenic novel variant in
exon 15 of DNM1 (NM_004408.3), the first documented
pathogenic variant in the PH domain. Although all previ-
ously reported patients with DNM1 pathogenic variants
exhibited epileptic encephalopathy and severe neurological
phenotype, the two probands in this report had no seizures
and exhibited mild to moderate DD/intellectual disability
(ID) and autism spectrum disorder. Our data suggest an
emerging and previously undescribed phenotype associated
with a specific DNM1 missense genetic variant in the PH
domain.
2 | CLINICAL REPORT
Patients 1 and 2 are monozygotic triplet sisters who pre-
sented for evaluation of DD, autism spectrum disorder,
some dysmorphic features, and hypotonia. They were born
at 36 weeks gestation, which was conceived naturally, via
an uncomplicated cesarian section secondary to triplet preg-
nancy. There were no complications after delivery. They
have a healthy triplet brother. Patient 1 had a birth weight
of 2.8 kg (>97th percentile for triplet gestation), a birth
length of 49 cm (>97th percentile), and an occipitofrontal
circumference (OFC) of 33.8 cm (80th percentile). Patient
2 had a birth weight of 2.55 kg (50th–90th percentile for
triplet gestation), a birth length of 48.2 cm (>97th centile),
and OFC of 33.1 cm (65th percentile). Their triplet brother
had a birth weight of 2.38 kg (50th–90th percentile for tri-
plet gestation), a birth length of 46.9 cm (97th percentile),
and OFC of 32 cm (40th percentile).
Developmental concerns were first noted at 4 months of
age when both sisters were noted to lack visual tracking,
but this spontaneously resolved at 7 months of age. Patient
1 and 2 started receiving physical, occupational, and speech
therapies at 1 year of age due to delayed speech and motor
milestones. Both sisters started sitting at 7–8 months,
crawling at 11 months, and walking at 18 months. At
18 months, Patient 1 could say 5–10 words, but lost most
of this vocabulary by age 2. Patient 2 had delayed lan-
guage acquisition but no language loss. Their triplet brother
started sitting at 6 months, crawling at 9 months and walk-
ing at 15 months. He required speech therapy for 9 months
during third year of life for mild speech delay. The brother
is in mainstream classes, never required any resources at
school, and does not exhibit neurobehavioral abnormalities.
The sisters were diagnosed with autism at 3 years of age
and have been receiving applied behavior analysis (ABA)
therapy since. At the age of 5, Patient 2 had one episode
of febrile seizure. She had a normal brain MRI after this
event. She also had a few staring episodes, but her EEG at
7 years of age was normal.
Developmental evaluation of both sisters at age 8 years
revealed that Patient 1 can say 15 words but rarely speaks.
She can add and subtract double digits, recognize sight
words, and use a few signs. She sometimes becomes agi-
tated and may bite or hit herself or others. Patient 2 can
use 50 words, combine 2–3 words, use many signs, write
her name, recognize some sight words, and complete some
basic addition and subtraction. She occasionally becomes
agitated, may hit herself or others, and refuses to cooperate
with therapy or schoolwork. Patient 2 receives Ritalin and
Clonidine for behavioral problems. A formal neuropsycho-
logical assessment was performed at 8 years of age for
both sisters and the detailed results are provided in
Appendix S1.
On physical exam at 8 years, Patient 1 and 2 had no
major dysmorphic features but were each noted to have a
broad forehead, smooth philtrum, widely spaced teeth,
high-arched palate, and mild retrognathia (Figure 1a,b).
Their neurological exam revealed mild axial and appendic-
ular hypotonia and drooling. Patient 1’s weight was 24 kg
(24th centile), height was 126.6 cm (28th centile) and OFC
was 53.3 cm (85th centile). Patient 2’s weight was 24.7 kg
(30th centile), height was 125.4 cm (22nd centile) and
OFC was 54.3 cm (95th centile).
The genetic workup of the Patient 1 and 2 started at
3 years of age and included normal karyotype, chromoso-
mal microarray analysis, and fragile X testing. Because of
muscle weakness and elevated blood lactate, the two sisters
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were diagnosed with a nonspecific mitochondrial disease.
However, mtDNA sequencing and deletion/duplication
studies and a mitochondrial nuclear gene panel were nor-
mal except for a variant of unknown significance,
p.Asp85Asn, in KCNE1. This finding prompted a cardiol-
ogy consultation and both sisters had a normal echocardio-
gram and EKG. The exome results (see below) prompted
an electroencephalogram which was normal in both sisters.
3 | MATERIALS AND METHODS
The Institutional Review Board of Washington University
School of Medicine approved our study protocol and
informed consent was obtained from the parents for publi-
cation of genetic results and photographs. Clinical whole-
exome sequencing was performed using a trio design with
one of the identical twin sisters submitted as a proband and
the second sibling and their parents used for segregation
analysis. For more details see Appendix S2.
4 | MOLECULAR RESULTS
Exome sequencing of the sisters identified a de novo,
heterozygous, likely pathogenic variant designated as
c.1603A>G (p.Lys535Glu) in DNM1. This variant has not
been observed in approximately 6,500 individuals that were
sequenced as part of the National Heart, Lung, and Blood
Institute (NHLBI) exome sequence project or in ExAC
database (http://exac.broadinstitute.org/). Both parents
tested negative for this variant.
5 | DISCUSSION
Pathogenic variants in DNM1 have been reported in associa-
tion with early-onset epileptic encephalopathy (including
West and Lennox-Gastaut syndromes), intractable seizures
starting within the first year of life, motor impairments, and
severe to profound ID (Allen et al., 2016; Deng et al., 2016;
Epi4K Consortium; Epilepsy Phenome/Genome Project,
2013; Euro E-RESC, EpilepsyPhenome/Genome P, Epi4K
Constorium, 2014; Nakashima et al., 2016) (Table 1). Other
rare clinical features reported in some individuals include
hypotonia, developmental regression, movement disorder,
autism, cortical visual impairment, behavioral concerns, and
microcephaly (Allen et al., 2016; Deng et al., 2016; Epi4K
Consortium; Epilepsy Phenome/Genome Project, 2013; Euro
E-RESC, EpilepsyPhenome/Genome P, Epi4K Constorium,
2014; Nakashima et al., 2016) (Table 1). The two patients
described here exhibit a milder phenotype with mild to mod-
erate ID, autistic symptoms, and other than a single febrile
seizure in Patient 2, no history of seizures.
The twin sisters studied here share the de novo variant,
c.1603A>G (p.Lys535Glu) in exon 15 of DNM1, classified
as likely pathogenic. This variant has not previously been
reported in patients or databases of healthy controls. It is a
nonconservative amino acid substitution that occurs at an
evolutionary conserved position (Figure S1). Previous
in vitro studies presented below further support the vari-
ant’s pathogenicity.
Eight previously reported patients with DNM1-related
disorder carry pathogenic variants in the GTPase domain
and two carry variants in the middle domain (Figure 2a).
To our knowledge, the monozygotic twin sisters in this
FIGURE 1 Facial features of Patient 1 & 2 and their brother. Note broad forehead, smooth philtrum, widely spaced teeth and mild
retrognathia in proband 1 (a) and proband 2 (b). The brother (c) exhibits no dysmorphic features except for mild hypertelorism
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study have the first reported PH likely pathogenic variant.
Our report indicates this variant in the PH domain causes
less functional impairments and leads to a less severe phe-
notype than variants in the GTPase or middle domains.
Dynamin is a family of proteins with GTPase activity
that facilitate vesicle scission (Achiriloaie, Barylko, &
Albanesi, 1999). In vitro studies showed that the expres-
sion of certain GTPase mutants decreased endocytosis
activity by interfering with vesicle scission during synaptic
vesicle endocytosis and a middle domain mutation dis-
rupted higher order DNM1 oligomerization (Dhindsa et al.,
2015). Experiments also showed that when residue 44 in
the GTPase domain of DNM1 was mutated, the protein had
reduced binding affinity for GTP and reduced fission activ-
ity (Lee, Frank, Marks, & Lemmon, 1999).
The PH domain is primarily responsible for binding
PIP2, yet the PH loop has been suggested to have constric-
tive functioning in the oligomer helix (Achiriloaie, Barylko,
& Albanesi, 1999). This structure bends to insert into the
plasma membrane and induce curvature before fission. In
vitro dominant negative inhibition variants of the PH
domain abolish phosphoinositide binding and knock out all
synaptic vesicle reuptake (Lee et al., 1999). Variants in the
PH domain of dynamin 1 have been previously studied by
Vallis et al. (1999) by creating a Lys535Ala mutant. The
position Lys535 was chosen because it comes into proxim-
ity to the 5’phosphate of the inositol ring in inositol-1,4,
5-trisphosphate (IP3). The point mutation described in that
article is at the same amino acid position as both patients
in our study. While Patients 1 and 2 have a Lys535Glu
variant, the mutated residue in that study is a Lys535Ala
substitution. Each of these amino acid substitutions are sig-
nificant because they do not share the same structure or
chemical properties as lysine. Multiple PH domain mutants
were compared, and while others did not show changed
levels of transferrin uptake, a well-established endocytosis
assay, Lys535Ala showed inhibition of endocytosis and
impairment of PIP2 binding (Vallis et al., 1999). These
findings support the critical role of Lys535 in the coordina-
tion of phosphoinositide binding, an essential step in endo-
cytosis (Vallis et al., 1999).
A similar study by Achiriloaie et al. (1999) compared
PH domain variants K535M and K561M to a GTPase
domain variant N272 (missing most of the GTPase domain)
and wild-type DNM1. The GTPase domain variant and
K535M both inhibited endocytosis, while the K561 mutant
and wild type DNM1 showed no significant difference in
endocytosis (Achiriloaie, Barylko, & Albanesi, 1999). This
implies that not all amino acid substitutions in the PH
domain are significant and reinforces the claim that Lys535
is essential to the PH loop binding to PIP2 and promoting
endocytosis. PH domain mutations at other sites may not
have a clinically discernable phenotype. We also examined
whether the position of the pathogenic variants affects dif-
ferent isoforms of Dynamin 1, but found all variants
involve all isoforms (Figure 2b).
FIGURE 2 (a) Exons 1–23 of DNM1,
based on transcript DNM1-009
(ENST00000341179.11). The genetic
variant described in this paper and
previously reported pathogenic variants are
shown in the diagram. The 5 important
Dynamin 1 domains are depicted.
(b) Diagram of the four common DNM1
isoforms (RefSeq: NM_004408.3, UniProt:
Q05193; dark blue rectangles). Numbers
refer to amino acids. The main protein
isoform is #1 and has 864 amino acids.
Light blue rectangles indicate different
amino acids compared to isoform 1. All
DNM1 variants are shown in relation to the
different isoforms
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In summary, Dynamin 1 is mainly expressed in the cen-
tral nervous system, explaining the neurological phenotype
in DNM1-related disorder. Previously reported patients
carry pathogenic variants in the GTPase or middle domains
and presented with epileptic encephalopathy and severe
neurodevelopmental symptoms. Here, we report the first
documented DNM1 variant in the PH domain associated
with a milder phenotype without epilepsy. Our data suggest
a novel, possibly unique, and less severe phenotype result-
ing from a variant in the PH domain of dynamin 1. Reports
of additional patients are needed to better define the geno-
type–phenotype correlation.
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